Zai Lab Analyst Ratings
Maintaining Hold on JOYY Inc. Amidst Seasonal Fluctuations and Aggressive Share Buybacks
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Bank of China Upgrades China Everbright Environment to Buy From Hold; Price Target Is HK$4.50
Maintaining Buy Rating on JOYY Inc: A Balanced View of Growth Prospects and Margin Improvements
Research Alert: CFRA Keeps Hold Opinion On Adss Of Joyy Inc
Analysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)
Maintaining Hold on JOYY: Assessing Valuation, Subsidiary Performance, and M&A Uncertainties
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)
JOYY Analyst Ratings
Analysts Offer Insights on Communication Services Companies: Tencent Holdings Limited (OtherTCTZF) and JOYY (YY)
Jefferies Adjusts JOYY Price Target to $42 From $44.40, Maintains Buy Rating
Morgan Stanley Adjusts JOYY Price Target to $37 From $40, Maintains Equalweight Rating
Citigroup Adjusts JOYY Price Target to $46 From $47, Maintains Buy Rating
Research Alert: CFRA Maintains Hold Opinion On Adss Of Joyy Inc
Buy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development Outlook
Zai Lab Analyst Ratings
Buy Rating on Zai Lab With a Target Price of $66 Amid Vyvgart's Growth Potential and Strategic Positioning